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Abstract
Alteration of androgen receptor function due to hormonally active compounds in the environment, may be responsible for impaired
reproductivefunctioninaquaticwildlife.Basedonhumanprostatecarcinoma22RV1cells,acellcultureexpressionsystemwasestablished
totesteffectsofputativeandrogenic/antiandrogeniccompoundsonendogenousgeneexpression.22RV1cellswereshowntoexpresshuman
androgen receptor, but not human progestin (hPR) or human oestrogen receptor (hER)  and . Six androgen-regulated genes (ARGs)
were chosen to determine androgenic/antiandrogenic action using highly sensitive real-time RT-PCR. Results showed that gene expression
is altered in a time-dependent manner. After stimulation of cells by DHT (10nM), synthetic androgen R1881 (1nM), or organic pesticides
(difenoconazole,fentinacetate,tetramethrin)TMPRSS2mRNAexpressionwasdown-regulatedbythefactor0.6after24hofDHTtreatment.
Similar results were obtained when cells were assayed for mRNA expression of PSA after fentinacetate and R1881 stimulation. In contrast,
TMPRSS2 expression was up-regulated by the factor 0.9 when cells were stimulated by tetramethrin. Final goal of the work is a sensitive
determination of differential gene expression by different compounds under study, achievement of substance-speciﬁc expression patterns
and function related analysis of potential androgens/antiandrogens.
© 2003 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Recent adverse trends in health and sexual development
of aquatic wildlife animals may be linked to the presence of
endocrine disruptors, i.e. substances that interfere with the
endocrine system, in the environment [1,2]. The concept that
environmental pollutants might have harmful effects on re-
production, is not based on theory, but is rather derived from
observations of wildlife biologists in the ﬁeld [3].E v e ni m -
pairment of sexual development and reproduction in humans
was proposed, although decrease of sperm counts during
the past 50 years [4] could not be conﬁrmed in worldwide
studies [5]. The increase of reproductive organs pathology
is commonly accepted for the last decades [6–9]. These dis-
eases might be hormone dependent, but till now a causal re-
lation between xenohormones and disorders observed could
notbeproven.Substanceswithandrogenicorantiandrogenic
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effects can be characterised as natural steroids originating
from human or animal metabolism [10], as phytooestrogens
and as synthetic androgens. From the ﬁrst group, we se-
lected DHT as a reference steroid. Synthetic androgens in-
clude medically used compounds in hormone replacement
therapy or growth promoters in farm animals [11,12] as well
as illegally used synthetic androgens for human or animal
doping. For our tests, we used synthetic androgen R1881.
The last group of androgenic/antiandrogenic substances in-
cludes chemicals or metabolites of chemicals showing hor-
monal activity as an unrequested side effect. Three of the
mostsuspiciousendocrinedisruptingchemicalsusedinplant
protection are included in our evaluation. Difenoconazole
and fentinacetate [13] are used as fungicides; the third—
tetramethrin—as an insecticide. Though known androgenic
or antiandrogenic substances can be detected at concentra-
tions in the ppt range by means of sensitive methods like
GC–MS, LC–MS or EIA [14,15], no statement on hor-
monal activity or effects on gene expression can be made
using these methods. To predict the inﬂuence of these com-
pounds on man or the environment, in vitro systems and
animal-based in vivo assays are available. In vitro assays
are based either on measurement of direct binding to the
isolated receptor, on induction of a reporter gene regulated
through the androgen responsive element (ARE) or on cell
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Table 1
Primer sequences, product length and melting temperature of six androgen-regulated genes and housekeeping gene
PSA PSM AR NKX3.1 TMPRSS2 PMEPA1
Forward Primer (bp) 29–46 1195–1214 252–272 568–586 1104–1123 895–918
Reverse Primer (bp) 107–187 1345–1364 558–578 740–761 1235–1254 1017–1040
Product length (bp) 159 170 326 261 151 146
Product melting temperature (◦C) 90.80 83.37 86.33 88.49 89.00 89.20
Selected genes are as follows: Prostate-speciﬁc antigen (PSA accession no. X14810) [41] belonging to kallekrein gene family is a common tumour marker
in cancer diagnosis, prostate-speciﬁc membrane antigen (PSM accession no. M99487) is a cell surface marker in the prostate [42], homeobox gene
NKX3.1 (accession no. U860669) [43] is involved in cell growth and differentiation, TMPRSS2 (accession no. AF270487) supports normal cell growth
and morphology [44], androgen receptor (AR accession no. M3423) [45], and PMEPA1 (accession no. AF224278) [46] is involved in calcium binding.
proliferation assays. Competitive receptor assays have been
established to measure binding afﬁnities of different sub-
stances [16]. Recently, Bauer et al. [17] succeeded in es-
tablishing a test system on the basis of recombinant human
AR. These assays can be performed on whole cells or cell
homogenates [18,19].
In recombinant reporter-gene assays after co-transfection
of cells, the ligand-activated receptors initiate transcription
of a reporter gene [20–23], e. g. luciferase. Activity of the re-
porter gene is directly related to the transcriptional activation
by the test compound. Both, yeast [24–26] and mammalian
cells are available. On cellular level, proliferation activity
of cells bearing naturally or recombinantly expressed AR
is used as test criterium. A negative proliferative effect of
androgens can be found in AR positive breast cancer cells
[27–29]. It can also be detected in AR transfected breast or
prostate cancer cells [30,31].
The assay described herein is based on induction or re-
pression of six marker genes selected from a collection of
previously identiﬁed androgen-regulated genes described,
e.g. in human prostate carcinoma cell line LNCaP. Choice-
criteria for androgen-regulated genes (ARGs) were as
follows: genes should have an ARE in the promoter region,
biological function should be known and genes should orig-
inate from different functional groups. All genes we choose
herein match these requirements. For overview see Table 1.
Transcriptional alterations were assayed by real-time poly-
merase chain reaction. In the present study, we show that a
cell-based endogenous gene expression assay is very sen-
sitive and can be used to assay androgen/antiandrogen-like
effects of various putative androgenic/antiandrogenic chem-
icals. Characteristic gene expression patterns could be
achieved for all substances under study.
2. Materials and methods
2.1. Reagents
Dihydrotestosterone (DHT, 5-androstan-17-ol-3-one)
was received from Sigma–Aldrich (Germany). R1881
(17-hydroxy-17-methylestra-4, 9, 11-trien-3-one) as a gift
from Schering AG (Germany). Difenoconazole and tetram-
ethrin were obtained from Dr. Ehrensdorfer (Germany),
fentinacetate from Riedel de Haën (Germany). Charcoal
(Norit A), and dextran (research grade, MG 65000-73000)
were purchased from Serva (Germany). All pesticides were
dissolved in ethanol p.a. (ﬁnal ethanol percentage of less
than 0.1%).
2.2. Cell culture
Human prostate carcinoma cell line 22RV1 [32] was
obtained from Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH (DSMZ, Germany, ACC 438)
and routinely cultured in 40% RPMI 1640 medium, 40%
Dulbecco’s MEM supplemented with 20% heat-inactivated
foetal bovine serum (FBS) plus 100,000 units/l penicillin
and 100mg/l streptomycin (Sigma, Germany). Steroids
were removed from FBS essentially as described by Darbre
et al. [33]. FBS was incubated with 0.5% activated charcoal
and 0.05% dextran T-70 for 30min at 55 ◦C the charcoal
particles were removed by centrifugation at 4 ◦C for 20min
at 4.500×g. This step was repeated and stripped serum was
sterile ﬁltered and stored in aliquots at −20 ◦C. All media
were obtained from Gibco-BRL (USA). Cells were split
1:6 every 7 days and cultures were maintained at 37 ◦Ci n
a humidiﬁed atmosphere of 5% CO2.
2.3. Cell treatment
Cells were seeded in medium containing 20% charcoal-
stripped FBS for 72h before treatment with steroids or pes-
ticides and allowed to form a conﬂuent monolayer. DHT
(10nM) or synthetic steroid R1881 (1nM) was added and
cells were harvested at 0, 6 and 24h after stimulation for
RNA extraction. Same procedure was carried out with other
ligands: difenoconazole (100nM), fentinacetate (100nM)
and tetramethrin (50nM). Control cultures were continu-
ously grown in steroid-depleted untreated medium for the
same intervals of time.
2.4. RNA isolation and reverse transcription reaction
Total RNA was isolated from 22RV1 cells using peq-
Gold TriFastTM (peqLab Biotechnologie GmbH, Germany)A. Hartel et al./Journal of Steroid Biochemistry & Molecular Biology 84 (2003) 231–238 233
with the guanidinium-isothiocyanate method [34] according
to the manufacturer’s instruction. Synthesis of ﬁrst strand
cDNA was performed by using 1000ng of total RNA and
200UMMLV-reversetranscriptase(Promega,USA)accord-
ing to the manufacturer’s protocol. RT reaction was carried
out in 40l reaction volume in a gradient cycler (Tgradient,
Biometra®, Germany).
2.5. Determination of nucleic acid concentration
All measurements of nucleic acid concentration were
performed at 260nm (OD260) in a spectrophotometer
(BioPhotometer®, Eppendorf, Germany) with 220–160nm
Uvettes® (Eppendorf).
2.6. Human oestrogen (hERα and β) and human progestin
(hPR) receptor expression analysis in the cell line 22RV1
TotalRNAfromuntreatedcellswasextractedandreverse-
transcribed as mentioned above. Expression of receptors
was investigated using following primers: progestin 5 -GA-
GAGCTCATCAAGGCAATTG-3  (sense) and 5 -CACCAT-
CCCTGCCAATATCTTG-3  (antisense) producing a 227bp
product; hER primers 5 -AGGGAAGCTCCTATTTGC-
TCC-3  (sense) and 5 -CGGTGGATGTGGTCCTTCTCT-3 
(antisense) yielding a 234bp product; hER 5 -GCTTCGT-
GGAGCTCAGCCTG-3  (sense) and 5 -AGGATCATGGC-
CTTGACACAGA-3  (antisense), generating a 262bp prod-
uct. Subsequently, PCR products were subjected to gel-
electrophoresis on 1.5% agarose gels containing 0.5g/ml
ethidium bromide.
2.7. Real-time PCR quantiﬁcation
Quantiﬁcation of genes of interest was carried out
in LightCycler® (Roche Diagnostic, Germany) using
LightCycler® DNA Master SYBR® Green I technology
[35]. Mastermixes for each PCR run were prepared as fol-
lows: 6.4l water, 1.2l MgCl2 (4mM), 0.2l Forward
Primer (20pmol), 0.2l Reverse Primer (20pmol) and 1l
Table 2
Characterisation of real-time LightCycler® PCR
NKX3.1 PMEPA1 TMPRSS2 PSA PSM AR Ubiquitin
Start template mRNA mRNA mRNA mRNA mRNA mRNA mRNA
PCR efﬁciency 1.90 1.92 1.98 2.07 2.13 1.99 1.99
Quantiﬁcation limit (ng) 0.2 0.04 0.04 0.2 0.04 0.04 0.04
Quantiﬁcation range (ng) 25–0.2 25–0.04 25–0.04 25–0.2 25–0.04 25–0.04 25–0.04
Test linearity correlation 22RV1 total
RNA (r = 1.00)
22RV1 total
RNA (r = 1.00)
22RV1 total
RNA (r = 0.98)
22RV1 total
RNA (r = 0.98)
22RV1 total
RNA (r = 0.99)
22RV1 total
RNA (r = 0.92)
22RV1 total
RNA (r = 0.95)
Intra-assay variation
(%, n = 3)
0.5 0.4 1.0 0.3 0.8 1.6 0.7
Inter-assay variation
(%, n = 3)
4.4 3.5 2.3 2.6 3.2 4.9 1.8
Intra-assay (test precision) and inter-assay variation (test variability), n = 3. Calculation of test precision and test variability is based on the variation of
crossing points (CP) from the CP mean value.
Fast Start DNA Master SYBR® Green I (Roche Diagnos-
tics, Germany) mix 9l of mastermix and 1l (25ng) of
reverse-transcribed total RNA. Each sample was subjected
to 40 cycles of PCR consisting of 15s at 95 ◦C for denatura-
tion, 10s at corresponding annealing temperature and 20s at
72 ◦C for elongation. Primers for all six androgen-regulated
genes were designed using HUSAR-software (DKFZ, Hei-
delberg) and synthesised by MWG Biotech (Germany). For
primer sequences and product length see Table 1.
Fluorescence data report was computed directly with
LightCycler® software 3.5 (Roche Diagnostics, Germany).
For the determination of crossing-points (CP) “Second
Derivative Maximum” method was applied [36]. Data anal-
ysis was performed using relative quantiﬁcation software
REST© [37]. Relative expression (E) was automatically
calculated according to equation: E = 2 CP. For depiction
of up/down regulation 2logE was determined to set gene
expression in control samples to zero.
2.8. Statistics
All data were statistically processed in SigmaPlot® 2000
(SPSS Inc., USA) and SigmaStat® 2.0 (Jandel Corporation,
USA).
3. Results
3.1. Characterisation of 22RV1 cell line
Using real-time RT-PCR 22RV1 cells showed expression
of human androgen receptor only. Neither mRNA of human
oestrogen receptor  and  (hER and ) nor mRNA of
human progestin receptor (hPR) could be detected (data not
shown).
3.2. Primer speciﬁcity, real-time RT-PCR efﬁciencies,
intra- and inter-assay variation
After real-time RT-PCR all primer pairs proved to gen-
erate amplicons showing one single melting peak with high234 A. Hartel et al./Journal of Steroid Biochemistry & Molecular Biology 84 (2003) 231–238
Fig. 1. Time response of DHT (10nM) induction of ARGs mRNA in 22RV1 cells. ∗P<0.01, ∗∗P<0.05 indicates signiﬁcant differences between
treatment groups.
speciﬁcity and high sensitivity. Length of desired product
was conﬁrmed by high-resolution gel-electrophoreses, (for
overview, see Table 2). After 40 cycles of real-time RT-PCR
noprimer–dimerformationcouldbeobserved.PCRefﬁcien-
cies were calculated from the given slopes in LightCycler®
Software 3.3 (Roche Diagnostic, Germany) (Table 2). To
conﬁrm accuracy and reproducibility of real-time PCR the
intra-assay precision was determined in replicates of three
within one LightCycler® run. Inter-assay variation was in-
vestigated in three different experimental runs performed on
Fig. 2. Time response of R1881 (1nM) induction of ARGs mRNA in 22RV1 cells. ∗P<0.01, ∗∗P<0.05 indicates signiﬁcant differences between
treatment groups.
3 days. Calculation of test precision and test variability is
based on the CP variation from the CP mean value (Table 2).
3.3. Screening for androgen-regulated genes
in 22RV1 cells
To test the different candidate marker genes, we exposed
22RV1 cells to either increasing concentrations of test com-
pound for 24h or a ﬁxed concentration for different time
periods. The candidate genes were then assayed for dose-A. Hartel et al./Journal of Steroid Biochemistry & Molecular Biology 84 (2003) 231–238 235
Fig. 3. Time response of fentinacetate (100nM) induction of ARGs mRNA in 22RV1 cells. ∗P<0.01, ∗∗P<0.05 indicates signiﬁcant differences
between treatment groups.
and time-dependent effects on mRNA expression. In this pa-
per, we present treatment dependent expression proﬁles for
six representative marker genes after 6 and 24h of treat-
ment. Dose- and time-settings presented here were chosen
according to optimal viability of treated cells and maximal
alteration of gene expression. Lower dosages did not lead
to signiﬁcant changes of gene induction/repression. Higher
doses,especiallyofpesticidesprovedtobecytotoxicinvitro.
Concentration of DHT and R1881 were adopted from cur-
rent literature [41,44,46].
Fig. 4. Time response of tetramethrin (50nM) induction of ARGs mRNA in 22RV1 cells. ∗P<0.01, ∗∗P<0.05 indicates signiﬁcant differences
between treatment groups.
3.4. Analysis of androgen-regulated gene expression in
different treatment groups
Our experimental conditions 10nM DHT treatment of
22RV1 cells for 6 and 24h revealed consistent up/down reg-
ulation of six prostate relevant androgen-regulated genes:
PSA, PSM, AR, NKX3.1, TMPRSS2, PMEPA1 (Fig. 1).
ARGs expression was also determined after 6 and 24h of
R1881 (1nM) treatment (Fig. 2). After 6h of culture treat-
ment, all genes appeared to be down-regulated. PMEPA1236 A. Hartel et al./Journal of Steroid Biochemistry & Molecular Biology 84 (2003) 231–238
Fig. 5. Time response of difenoconazole (100nM) induction of ARGs mRNA in 22RV1 cells. ∗P<0.01, ∗∗P<0.05 indicates signiﬁcant differences
between treatment groups.
gene expression was up-regulated after 24h whereas all
other genes remained down-regulated (Fig. 2). Homeobox
NKX3.1 gene was down-regulated by the factor 1.9 after 6h
in response to fentinacetate (Fig. 3). After 24h, there was
less than factor 0.1 increase in NKX3.1 mRNA levels.
All six ARGs had no statistically signiﬁcant increase at
least 6h after tetramethrin (Fig. 4) treatment. After 24h, we
detected induction of PSA by the factor 0.7 and of TMPRSS2
(0.9) by tetramethrin. Prolonged treatment with 100nM
difenoconazole produced a further increase of NKX3.1 tran-
scription with a 0.5 and 2.1 increase of mRNA after 6 and
24h, respectively (Fig. 5). For complete depiction of gene
expression pattern see Figs. 1–5.
4. Discussion
The herein described assay is based on human prostate
carcinoma 22RV1 that is an androgen-dependent, serially
transplantable nude mouse xenograft derived from a pri-
mary human prostate cancer. Transplanted 22RV1 tumours
are positive for AR and growth of 22RV1 is androgen de-
pendent. The recurrent tumour 22RV1 expresses AR, but
growth of this tumour becomes androgen independent [38].
As DSMZ could deﬁnitely not assure expression of hAR in
22RV1 cells only, receptor expression had ﬁrst to be char-
acterised. 22RV1 cells proved to express human androgen
receptor only. Therefore, conclusion can be made that alter-
ation of gene expression patterns may predominately be re-
lated to androgenic/antiandrogenic function of compounds
under study. Nevertheless, induction/repression of gene ac-
tivity due to an androgen independent pathway cannot to-
tally be excluded. However, interferences with oestrogen or
progestin signalling pathways are not possible in our sys-
tem, because of lack of receptor expression. All other com-
mercially available prostate cancer cell lines do express at
least one additional steroid receptor. Therefore, they are not
suited for selective androgen-related bioresponse analysis.
Since one of the primary goals of our study was to deﬁne a
panel of ARGs that could be used as a readout for androgen
signaling status, setting, dosage and time of androgen treat-
ment of 22RV1 cells selected for real-time analysis had to
be established. Expression of all genes under study showed
to be androgen dependent, although growth of cells was in-
dependent from the presence of androgens in the media.
All primers used, ampliﬁed the sequences of interest
with excellent accuracy and precision. Intra- and inter-assay
variances proved to be as low as mentioned by others
[39]. Therefore, even slight differences in gene expression
were statistically signiﬁcant. Non-signiﬁcant differences
in expression patterns indicated by higher bars than lower
but signiﬁcant bars, are caused by higher variability in
inter-assay performance of respective genes. An important
parameter for us when selecting target genes, is that tran-
scriptional alteration is highly sensitive to the treatment.
Moreover, gene expression must be directly regulated by
androgens/antiandrogens. For this purpose only genes bear-
ing an ARE in were included in this study. In contrast to
GAPDH or -actin, ubiquitin expression was unaffected by
cell treatment. Therefore, we chose ubiquitin for normali-
sation of target gene expression in the different treatment
groups.
Finding that gene expression patterns in 22RV1 cells
are altered in a time-dependent matter, suggests that stud-
ies on endogenous gene expression could be a useful
tool for assaying compounds with potential androgenic/A. Hartel et al./Journal of Steroid Biochemistry & Molecular Biology 84 (2003) 231–238 237
antiandrogenic effects. After treatment with different com-
pounds, each of them revealed a substance-speciﬁc expres-
sion pattern. NKX3.1 proved to be the only gene, which
was down-regulated in expression in all treatment groups.
These observations contrast results of others [43], who were
able to show that NKX3.1 expression is up-regulated upon
androgen treatment of LNCaP cells. Tetramethrin treatment
for 6h showed the weakest effect on gene expression. Using
this compound in an androgen-receptor binding assay [40]
revealed only weak relative binding activity and may there-
fore not be able to induce strong gene expression activity. In
addition, it could be proven that various genes can respond
differently to different putative androgens/antiandrogens.
Nevertheless, using this system it remains unclear whether
expression patterns found, will culminate in an andro-
genic/antiandrogenic effect when acting on a complex
organism. To predict the inﬂuence of these compounds on
man or livestock, animal-based in vivo assays still have to
be carried out. They indicate complex changes in phenotype
of test organisms as a result of various cell types interact-
ing differently with the substances under study. Therefore,
determination of androgenic/antiandrogenic effects leading
to pathological alterations like cryptorchism, hypospadias,
testicular cancer, prostate cancer and breast cancer still
have to be analysed using animal experiments. Furthermore
foetotoxic effects and impairement of fertility in the next
generation can be assayed by animal experiments only.
On the other hand, reporter-gene assays are available to
test androgenicity of chemicals or metabolites [20–23]. Con-
cerning reporter-gene systems it has to be mentioned that
artiﬁcially constructed plasmids are far apart from the more
complex androgen dependent endogenous gene expression.
Nevertheless, these assays show high sensitivity facilitating
the distinction between receptor agonists and antagonists.
However, expression of one gene of interest only can be
measured in these systems, they are not suitable to achieve
substance-speciﬁc expression patterns. Complex inﬂuences
on gene expression like induction of one gene and repres-
sion of another one cannot be covered by reporter-gene
assays. The third method established are the binding as-
says [16–19] that allow studies on binding efﬁciencies
only. No statement concerning a functional bioresponse
can be made. Distinction between different compounds
concerning binding efﬁciencies can only made in a “yes”
or “no” manner. Therefore, these tests are hardly suited
for functional analysis of substances. Due to the disadvan-
tages of above-mentioned methods, we decided to choose
an approach using an endogenous gene expression system.
All this has been done with respect to characterisation
and achievement of substance-speciﬁc expression pattern.
Our test system revealed that changes in gene expression
levels show a quantitative time-response-correlation. Re-
sults obtained, showed that cell harvest and gene expres-
sion analysis after 6h of treatment is sufﬁcient to get
substance-speciﬁc expression patterns. In conclusion, ap-
plying an endogenous-gene expression system facilitates
the characterisation of the different activity spectra of an-
drogenic/antiandrogenic substances.
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